BrightHeart

BrightHeart is an AI medical device company developing the B-Right AI Platform, which empowers clinicians and sonographers with expert-level prenatal ultrasound capabilities. The platform delivers real-time AI analysis of fetal heart structures to detect congenital heart defects (CHDs) during routine prenatal scans, achieving 98.7% sensitivity for severe CHD indicators and 97.7% specificity in confirming normality. BrightHeart's technology reduces false-positive errors by 88%, reduces false-negative errors by 70%, and decreases incomplete fetal heart scans by 47%. Founded by fetal cardiologists Marilyne Levy and Bertrand Stos based in Paris, the company has received FDA clearance and CE Mark for its B-Right software. The platform integrates as a plug-and-play solution compatible with major ultrasound manufacturers and existing reporting workflows, displaying results on a cart-side tablet in real time during scanning. BrightHeart is addressing a critical gap in prenatal care: congenital heart defects are the most common birth defect worldwide, yet up to 70% go undetected during pregnancy. The company secured an €11 million Series A round in early 2026 co-led by ODYSSEE Venture and GO CAPITAL.